Nature of Business (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Nature of Business [Abstract]
Number of programs in clinical development for cancer indications	2
Estimated Projected Expenditure Type [Line Items]
Cash and cash equivalents	$ 14,344,088	$ 17,988,590	$ 6,324,430	$ 9,893,590
Marketable securities	24,000,000	18,057,672
Projected expenditures for clinical programs	25,200,000
Aldoxorubicin [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	8,300,000
Tamibarotene [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	3,700,000
General Operation [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	6,700,000
Other General and Administrative Expenses [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	$ 6,500,000